Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.85 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.69 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16586807 | 0.92 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16592372 | 0.84 | NTRK1 (0.71) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16585763 | 0.84 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16592378 | 0.83 | NTRK1 (0.69) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16586406 | 0.82 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16585651 | 0.82 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 | |
| SCHEMBL17111688 | 0.82 | NTRK1 (0.59) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16585658 | 0.80 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 | |
| SCHEMBL17111415 | 0.80 | NTRK1 (0.57) | NTRK1NTRK3NTRK2 | |
| SCHEMBL17111814 | 0.80 | NTRK1 (0.57) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3046554-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042088-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015039334-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGF, NGFR, NTRK2 | NTRK1 4/4885NTRK3 5/4885NTRK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.